ENT Treatment Market Size - Global Industry, Share, Analysis, Trends and Forecast 2022 – 2030

The Global ENT Treatment Market Size accounted for USD 21.1 Billion in 2021 and is estimated to garner a market size of USD 33.9 Billion by 2030 rising at a CAGR of 5.5% from 2022 to 2030. Increasing air and noise pollution is one of the significant factors that drive the ear, nose, and throat (ENT) market growth. The ENT disorder treatment is very common in the world today and it can cause severe healthcare issues for all age groups. The rising elderly population is another factor that is supporting the global ENT disorder treatment industry. Furthermore, growing R&D to discover new treatment methods for these patients is a very popular ENT treatment market trend that will fuel the demand in the coming years.

ENT Treatment Market Report Key Highlights

• Global ENT treatment market revenue is estimated to reach USD 33.9 Billion by 2030 with a CAGR of 5.5% from 2022 to 2030
• North America ENT treatment market share accounted for over 37% regional shares in 2021
• According to the CDC statistics, around 30% of all hearing loss cases in Europe are due to noise pollution
• Asia-Pacific ENT treatment market growth will record fastest CAGR from 2022 to 2030
• Based on organ type segment, Nose accounted for approx 50% of the overall market share in 2021
• Rising prevalence of anti-bacterial resistance propels the ear, nose, and throat (ENT) treatment market value in coming years

An increase in the number of patients suffering from ENT problems across the globe, rapid advancements in the development of advanced treatment, and a rise in awareness among consumers related to the availability of minimally invasive surgical procedures are major factors expected to drive the growth of global ear, nose, and throat treatment market. According to the World Health Organization (WHO), nearly 2.5 billion people across the globe, or one in every four, will have some degree of hearing loss by 2050. Centers for Disease Control and Prevention states that: out of every 1,000 children, about 2 to 3 are born with hearing loss in both ears in the US. In addition, approximately 15% of American adults (37.5 million) aged 18 and over report some trouble hearing. Tonsillitis, sinus infections, and ear infections are some of the major ENT problems witnessed by doctors every year. According to Getting It Right First Time (GIRFT), UK statistics, 330,000 patients were admitted to hospitals with ENT disorders. Also, tonsillectomy accounts for 17% of the total elective workload, with 2.8 million outpatient visits. Consumer spending on healthcare is increasing and with the availability of advanced healthcare infrastructure their approach towards the availability of better care to patients is increasing.

Global ENT Treatment Market Dynamics

Market Drivers

• Growing air and noise pollution
• Rising development of antibiotics
• Surging minimally invasive procedures
• Rapid innovation in development of advanced treatment

Market Restraints

• High cost of medical devices and drugs for tonsillitis and sinusitis
• Lack of awareness in emerging economies

Market Opportunities

• Increasing penetration of robotics in ENT treatment procedures
• Surplus investments in healthcare infrastructure

ENT Treatment Market Report Coverage

ENT Treatment Market Dynamics

The rise in the geriatric population in developing countries and the increase in problems associated with hearing among them is expected to increase demand for minimally invasive devices and treatment procedures. In addition, increasing penetration of robotics in treatment procedures in order to deliver high precision in the diagnosis of diseases are some factors expected to boost the ear, nose, and throat (ENT) treatment market growth. The government is spending high on the development of present infrastructure with a focus to deliver enhanced care to the patients and aiding enterprises in R&D activities. For instance, NHS spends approximately US$ 37.5 million on ENT products and technologies among which cochlear implants, bone-anchored hearing aids (BAHAs), processors, and accessories account for 80% of these expenditures. The government is providing better reimbursement policies to consumers in order to facilitate healthcare treatment. For example:

• The UK provides complete free healthcare in some parts of the country. If the person/patient is S2 approved then the UK government will be solely in charge of the patient's care. The 100% cost of patient treatment would be covered by the government.
• European Health Insurance Card (EHIC), is a healthcare service for (European Economic Area) EEA countries where it covers all the costs of patients in any unplanned medical situation with state-funded treatment. EHIC will reimburse the cost of treatment.

ENT Treatment Market Segmentation

The worldwide ENT treatment market is split based on organ type, treatment type, end-user, and geography.

ENT Treatment Market By Organ Type

• Ears
• Nose
• Throat

According to our ENT treatment industry analysis, the nose organ accumulated a significant market share in 2021. Additionally, the ear segment is expected to attain a substantial growth rate in the coming years. This is attributed to raise in number of ear infection cases across the globe. Increasing R&D activities by major players and introduction of innovative devices is expected to support the segment growth.

ENT Treatment Market By Treatment Type

• Devices
• Drugs

As per our ENT treatment market forecast, the drugs segment dominated the global ENT treatment market with noteworthy share from 2022 to 2030. However, the devices sub-segment would spur with a considerable growth rate during the forecasted timeframe. The rising innovation in developing new devices for diagnosis and treatment of ear, nose, and throat are likely to support the segment in the coming years.

ENT Treatment Market By End-User

• Hospitals
• Clinics
• Home Care Settings
• Others

Among end-users, the hospital's segment accounted for the highest ENT disorder treatment market share in 2021, due to increasing government spending on the development of hospital infrastructure and focus to deliver enhanced care to the patients. On the other hand, the home care settings are on a boom due to the advent of COVID-19 pandemic and the rising disposable income coupled with the highly aware population regarding the treatment if ear, nose, and throat (ENT).

ENT Treatment Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Latin America

• Mexico
• Brazil
• Rest of Latin America

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

The Middle East & Africa (MEA)

• Gulf Cooperation Council (GCC)
• South Africa
• Rest of the Middle East & Africa

In 2021, North America held the major share of the global ENT Treatment market

North America accounted for revenue of US$ 7.8 billion in 2021 and is expected to continue its dominance over the market due to the rising number of patients suffering from various ear and nose infections. The availability of favorable reimbursement policies by the government and the presence of advanced healthcare infrastructure are expected to impact the growth of ear, nose, and throat disorder treatment market. Consumer preference for home care is increasing; with the availability of developed infrastructure adoption of advanced devices is easy to provide patients better care. The presence of a large number of players operating in the country and the introduction of new solutions is expected to boost the ear, nose, and throat (ENT) treatment market growth. The government is providing favorable policies for product approvals. In 2019, the Food and Drug Administration (FDA), approved "Dupixent (dupilumab)" to treat adults with nasal polyps and chronic rhinosinusitis. This is the first treatment approved by the FDA for inadequately controlled chronic rhinosinusitis with nasal polyps.

ENT Treatment Market Players

The global ENT treatment companies profiled in the report include Medtronic plc, Cochlear Limited, Sanofi, Pfizer Inc., Merck & Co., Inc., Johnson and Johnson Olympus Corporation, Smith & Nephew plc, Siemens Healthcare GmbH, Starkey Laboratories, Inc, and Demant A/S.